Stimulation of tumors to synthesize tumor necrosis factor-α in situ using 5,6-dimethylxanthenone-4-acetic acid: A novel approach to cancer therapy

Cancer Research

Volumn 59, Issue 3, 1999, Pages 633-638

  Joseph, Wayne R ^a   Cao, Zhihui ^a   Mountjoy, Kathleen G ^b   Marshall, Elaine S ^a   Baguley, Bruce C ^a   Ching, Lai Ming ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER TRANSPLANTATION; CYTOKINE PRODUCTION; DRUG EFFECT; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INTRAPERITONEAL DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; LIPOPOLYSACCHARIDES; LIVER; MELANOMA; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, NUDE; NEOPLASM TRANSPLANTATION; OVARIAN NEOPLASMS; RNA, MESSENGER; SPLEEN; STIMULATION, CHEMICAL; TRANSPLANTATION, HETEROLOGOUS; TUMOR NECROSIS FACTOR-ALPHA; XANTHENES; XANTHONES;

EID: 0033083206     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Carswell, E. A., Old, L. J., Kassel, R. L., Green, S., Fiore, N., and Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA, 25: 3666-3670, 1975.
2. Old, L. J. Tumor necrosis factor (TNF). Science (Washington DC), 230: 630-632, 1985.
3. Havell, E. A., Fiers, W., and North, R. J. The antitumor function of tumor necrosis factor (TNF). I. Therapeutic action of TNF against an established murine sarcoma is indirect, immunologically dependent, and limited by severe toxicity. J. Exp. Med., 167: 1067-1085, 1988.
4. Nakano, K., Abe, S., and Sohmura, Y. Recombinant human tumor necrosis factor - I. Cytotoxic activity in vitro. Int. J. Immunopharmacol., 8: 347-355, 1986.
5. Manda, T., Shimomura, K., Mukumoto, S., Kobayashi, K., Mizota,. T., Hirai, O., Matsumoto, S., Oku, T., Nishigaki, F., Mori, J., and Kikiuchi, H. Recombinant human tumor necrosis factor-α: evidence of an indirect mode of antitumor activity. Cancer Res., 47: 3707-3711, 1987.
6. Watanabe, N., Niitsu, Y., Umeno, H., Kuriyama, H., Neda, H., Yamauchi, N., Maeda, M., and Urushizaki, I. Toxic effect of tumor necrosis factor on tumor vasculature in mice. Cancer Res., 48: 2179-2183, 1988.
7. Nawroth, P. P., and Stern, D. M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med., 163: 740-745, 1986.
8. Bevilacqua, M. P., Pober, J. S., Majeau, G. R., Fiers, W., Cotran, R. S., and Gimbrone, M. A., Jr. Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. Proc. Natl. Acad. Sci. USA, 83: 4533-4537, 1986.
9. Ferrero, E., Villa, A., Ferrero, M. E., Toninelli, E., Bender, J. R., Pardi, R., and Zocchi, M. R. Tumor necrosis factor α-induced vascular leakage involves PECAM1 phosphorylarion. Cancer Res., 56: 3211-3215, 1996.
10. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. Blood flow failure as a major determinant in the antitumor action of flavone acetic acid (NSC 347512). J. Natl. Cancer. Inst. (Bethesda). 81: 1005-1013, 1989.
11. Berendt, M. J., North, R. J., and Kirstein, D. P. The immunological basis of endotoxin-induced tumour regression. Requirement for a pre-existing state of concomitant anti-tumour immunity. J. Exp. Med., 148: 1560-1569, 1978.
12. Mackay, F., Loetscher, H., Stueber, D., Gehr, G., and Lesslauer, W. Tumor necrosis factor α (TNF-α)-induced cell adhesion to human endothelial cells is under dominant control of one TNF receptor type, TNF-R55. J. Exp. Med., 177: 1277-1286, 1993.
13. Osborn, L., Hession, C., Tizard, R., Vassallo, C., Luhowskyj, S., Chi-Rosso, G., and Lobb, R. Direct expression cloning of vascular cell adhesion molecule 1, a cytokine-induced endothelial protein that binds to lymphocytes. Cell, 59: 1203-1211, 1989.
14. Rice, G. E., and Bevilacqua, M. P. An inducible endothelial cell surface glycoprotein mediates melanoma adhesion. Science (Washington DC), 246: 1303-1306, 1989.
15. Carlos, T. M., Schwartz, B. R., Kovach, N. L., Yee, E., Rosa, M., Osborn, L., Chi-Rosso, G., Newman, B., Lobb, R., and Harlan, J. M. Vascular cell adhesion molecule-1 mediates lymphocyte adherence to cytokine-activated cultured human endothelial cells. Blood, 76: 965-970, 1990.
16. Creaven, P. J., Brenner, D. E., Cowens, J. W., Huben, R. P., Wolf, R. M., Takito, H., Arbuck, S. G., Razak, M. S., and Proefrock, A. D. A Phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol., 23: 186-191, 1989.
17. Rosenberg, S. A., Spiess, P., and Lafreniere, R, A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (Washington DC), 231: 1318-1321, 1986.
18. Lienard, D., Ewalenko, P., Delmotte, P., Renard, J. J., and Lejeune, F. High-dose recombinant tumor necrosis factor α in combination with interferon γ and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J. Clin. Oncol., 10: 52-60, 1992.
19. Weichselbaum, R. R., Hallahan, D. E., Beckett, M. A., Mauceri, H. J., Lee, H., Sukhatme, V. P., and Kufe, D. W. Gene therapy targeted by radiation preferentially radiosensitizes tumor cells. Cancer Res., 54: 4266-4269, 1994.
20. Mauceri, H. J., Hanna, N. N., Wayne, J. D., Hallahan, D. E., Hellman, S., and Weichselbaum, R. R. Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res., 56: 4311-4314, 1996.
21. Merrouche, Y., Negrier, S., Bain, C., Combaret, V., Mercatello, A., Coronel, B., Moskovtchenko, J. F., Tolstoshev, P., Moen, R., Philip, T., and Favrot, M. C. Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin. J. Clin. Oncol., 13: 410-418, 1995.
22. Starnes, C. O. Coley's toxins in perspective. Nature (Lond.), 357: 11-12, 1992.
23. Engelhardt, R., Mackensen, A., and Galanos, C. Phase I trial of intravenously administered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res., 51: 2524-2530, 1991.
24. Jaeckle, K. A., Mittelman, A., and Hill, F. H. Phase II trial of Serratia marcescens extract in recurrent malignant astrocytoma. J. Clin. Oncol., 8: 1408-1418, 1990.
25. Rewcastle, G. W., Atwell, G. J., Zhuang, L., Baguley, B. C., and Denny, W. A. Potential antitumor agents. 61. Structure-activity relationships for in vivo colon-38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids. J. Med. Chem., 34: 217-222, 1991.
26. Ching, L.-M., Joseph, W. P., and Baguley, B. C. Stimulation of macrophage tumoricidal activity by 5.6-dimethylxanthenone-4-acetic acid, a potent analogue of the antitumor agent flavone-8-acetic acid. Biochem. Pharmacol., 44: 192-195, 1992.
27. Baguley, B. C., and Ching, L. M. Immunomodulatory actions of xanthenone anti-cancer agents. BioDrugs, 8: 119-127, 1997.
28. Kerr, D. J., and Kaye, S. B. Flavone acetic acid: preclinical and clinical activity. Eur. J. Cancer Clin. Oncol., 25: 1271-1272, 1989.
29. Pratesi, G., Rodolfo, M., Rovetta, G., and Parmiani, G. Role of T cells and tumour necrosis factor in antitumour activity and toxicity of flavone acetic acid. Eur. J. Cancer, 26: 1079-1083, 1990.
30. Mahadevan, V., Malik, S. T. A., Meager, A., Fiers, W., Lewis, G. P., and Hart, I. R. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res., 50: 5537-5542, 1990.
31. Ching, L. M., Joseph, W. R., Crosier, K. E., and Baguley, B. C. Induction of tumor necrosis factor-α messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res., 54: 870-872, 1994.
32. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. Correlation between immune and vascular activities of xanthenone acetic acid antitumor agents. Oncol. Res., 6: 79-85, 1994.
33. Lash, C. J., Li, A. E., Rutland, M., Baguley, B. C., Zwi, L. J., and Wilson, W. R. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxane-thenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs. Br. J. Cancer, 78: 439-445, 1998.
34. Zwi, L. J., Baguley, B. C., Gavin, J. B., and Wilson, W. R. The morphological effects of the anti-tumour agents flavone acelic acid and 5,6-dimethylxanthenone acetic acid on the colon 38 mouse tumour. Pathology, 26: 161-169, 1994.
35. Philpott, M., Baguley, B. C., and Ching, L-M. Induction of tumour necrosis factor-α by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother. Pharmacol., 36: 143-148, 1995.
36. Ching, L. M., Joseph, W. R., Zhuang, L., and Baguley, B. C. Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours. Cancer Chemother. Pharmacol., 35: 153-160, 1994.
37. Marshall, E. S., Holdaway, K. M., Shaw, J. H. F., Finlay, G. J., Matthews, J. H. L., and Baguley, B. C. Anticancer drug sensitivity profiles of new and established melanoma cell lines. Oncol. Res., 5: 301-309, 1993.
38. 3H]thymidine incorporation and soft agar clonogenic assays. Eur. J. Cancer, 30A: 1370-1376, 1994.
39. Baguley, B. C., Marshall, E. S., Whittaker, J. R., Dotchin, M. C., Nixon, J., McCrystal, M. R., Finlay, G. J., Matthews, J. H. L., Holdaway, K. M., and van Zijl, P. Resistance mechanisms determining the in vitro sensitivity to paclitaxel of tumour cells cultured from patients with ovarian cancer. Eur. J. Cancer, 31A: 230-237, 1995.
40. Hogan, M. M., and Vogel, S. N., Measurement of tumor necrosis factor a and β. In: J. E. Coligan, A. M. Kruisbeek, D. H. Margulies, E. M. Shevach, and W. Strober (eds.), Current Protocols in Immunology, Vol. 1, p. 6.10.1. New York: Greene Publishing Associates and Wiley Interscience, 1990.
41. Wright, S. D., Ramos, R. A., Tobias, P. S., Ulevitch, R. J., and Mathison, J. C. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science (Washington DC), 249: 1431-1433, 1990.
42. Lei, M. G., Stimpson, S. A., and Morrison, D. C. Specific endotoxic lipopolysaccharide-binding receptors on murine splenocytes. III. Binding specificity and characterization. J. Immunol., 147: 1925-1932, 1991.
43. Lee, J. D., Kato, K., Tobias, P. S., Kirkland, T. N., and Ulevitch, R. J. Transfection of CD14 into 70Z/3 cells dramatically enhances the sensitivity to complexes of lipopolysaccharide (LPS) and LPS binding protein. J. Exp. Med., 175: 1697-1705, 1992.
44. Shweiki, D., Itin, A., Soffer, D., and Keshet, E. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (Lond.), 359: 843-845, 1992.
45. Lawson, C. A., Yan, S. D., Yan, S. F., Liao, H., Zhou, Y. S., Sobel, J., Kisiel, W., Stern, D. M., and Pinsky, D. J. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J. Clin. Invest., 99: 1729-1738, 1997.
46. Carmeliet, P., Dor, Y., Herbert, J. M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., Koch, C. J., Ratcliffe, P., Moons, L., Jain, R. K., Collen, D., and Keshet, E. Role of HIF-1-α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature (Lond.), 394: 485-490, 1998.
47. Pipili-Synetos, E., Sakkoula, E., and Maragoudakis, M. E. Nitric oxide is involved in the regulation of angiogenesis. Br. J. Pharmacol., 108: 855-857, 1993.
48. Thomsen, L. L., Ching, L. M., Zhuang, L., Gavin, J. B., and Baguley, B. C. Tumor-dependent increased plasma nitrate concentrations as an indication of the antitumor effect of flavone-8-acetic acid and analogues in mice. Cancer Res., 51: 77-81, 1991.
49. Melillo, G., Taylor, L. S., Brooks, A., Cox, G. W., and Varesio, L. Regulation of inducible nitric oxide synthase expression in IFN-γ-treated murine macrophages cultured under hypoxic conditions. J. Immunol., 157: 2638-2644, 1996.
50. Leibovich, S. J., Polverini, P. J., Shepard, H. M., Wiseman, D. M., Shively, V., and Nuseir, N. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature (Lond.), 329: 630-632, 1987.
51. Ching, L. M., Joseph, W. R., and Baguley, B. C. Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice. Br. J. Cancer, 66: 128-130, 1992.
52. Bibby, M. C., Phillips, R. M., Double, J. A., and Pratesi, G. Anti-tumour activity of flavone acetic acid (NSC-347512) in mice: influence of immune status. Br. J. Cancer, 63: 57-62, 1991.